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Abstract 
 
Objective(s) 
In addition to antihypertensive effects, amlodipine may exhibit cardiovascular protective effects in heart 
tissue. The aim of this study was to evaluate the effects of amlodipine and/or high cholesterol diet on blood, 
heart tissue concentration and mRNA expression of endothelin-1 (ET-1) in male New Zealand white rabbits. 
Materials and Methods 
A total of 40 male New Zealand rabbits were divided into four groups: the normal control group, normal 
group receiving amlodipine, high-cholesterol diet group and high-cholesterol diet with amlodipine group. 
After 8 weeks, all the animals anesthetized and blood or tissues samples were collected. 
Results 
After 8 weeks of a high cholesterol diet, the group with such a diet had a significantly higher ratio of left 
ventricle (LV) weight to body weight
 than the control group (P= 0.0001). After treatment with amlodipine 
for 8 weeks, ET-1 level was reduced considerably in comparison with the control (P= 0.01) and high-
cholesterol diet groupes (P= 0.01). Amlodipine consumption caused significant reduction (P= 0.01) in the 
level of ET-1 in heart tissues of high-cholesterol diet group but it had no remarkable effect on the reduction 
of heart tissue ET-1 in amlodipine group compared with the control group.  
Conclusion 
The present study demonstrates that ventricular
 prepro-ET-1 mRNA quantitatively increases in the high-
cholesterol
 diet rabbits which results in development of ventricular hypertrophy. It seems that the treatment 
with amlodipine retards
 the progression of LV hypertrophy through attenuation
 of ET-1 levels independent of 
lipid changes.  
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Introduction 
Obesity is a fast growing problem reaching 
epidemic proportions worldwide (1) and 
individuals with severe obesity have long been 
recognized to have a form of cardiomyopathy 
attributed to chronic volume overload, 
characterized by left ventricular (LV) dilation, 
increased LV wall stress, and adaptation LV 
hypertrophy (2), leading to heart failure (3, 4). 
Myocardial hypertrophy in response to 
pathological stimuli has traditionally been seen 
as an adaptive response of cardiac muscle to 
the altered conditions of haemodynamic load, 
during which the increase in wall thickness 
fulfils the function of regaining normal wall 
stress (5). Castelli and Anderson, 1986 have 
reported that LV mass regression reduced 
cardiovascular complications. Reverse of LV 
mass has been accepted as a high goal in 
treatment of cardiovascular disease (6). 
The 21- amino acid peptide endothelin-1           
(ET-1) is produced by vascular endothelial 
cells from the 38-amino acid precursor 
peptide, big ET-1, by the endothelin 
converting enzyme. ET-1 may contribute to 
the progression of several cardiovascular 
disorders such as congestive heart failure, 
hypertension and ischemic heart disease (7). 
ET-1 levels have been shown to be increased 
in
 hypercholestolemic animals (8) and patients 
(9). Endothelin in addition to its vasoactive 
properties, also
 triggers hypertrophic signaling 
pathways by activation of extracellular
 signal-
regulated kinase in myocardium (10), thereby 
implying
  a potential involvement of this 
peptide in the initiation and
  progression of 
ventricular hypertrophy. In vivo, gene 
knockout
 of the ET-1 gene has been reported 
to inhibit ventricular hypertrophy
 (11). 
It has been reported that calcium channel 
blockers (CCBs) have the potential to prevent 
the cardiovascular disease and atherosclerosis 
(12). Amlodipine is considered as one of the 
1,4-dihydropyridine calcium antagonists which 
has a long elimination half-life and has a good 
indication of the ability to interfere with the 
cell membrane function which affects on the 
calcium permeability resulting in calcium 
inhibition in vascular SMC and reduction of 
atherosclerotic lesions (13). However, other 
studies have been unable to verify this 
correlation (14), so the issue remains to be 
clarified. The effect was manifested different 
in animal experiments (15). Amlodipine may 
also positively influence on the risk factors 
that are correlated with atherosclerosis. 
However, all the mechanisms which are 
involved are not clear. The main aim of this 
research was to evaluate the effects of 
amlodipine and/or high cholesterol diet on the 
heart tissue concentration, mRNA expression 
of endothelin and also the progression of 
ventricular
 hypertrophy which, so far has not 
been performed in rabbit model. Thus, the 
present study probably provides valuable 
information about the pathogenesis of 
atherosclerosis. This research may provide 
also a closer view of amlodipipne effect and 
may employ strategies to provide evidences to 
show an anti myocardial hypertrophic role via 
performing the effects of ET-1 mRNA 
expression in hypercholesterolemia New 
Zealand rabbits. 
 
Materials and Methods 
Animals  
A total of 40 male New Zealand white rabbits 
(1.4 kg at the beginning) were divided into 4 
groups: the normal control group (NC), normal 
group receiving amlodipine (NA), high-
cholesterol diet group (HC) and high-
cholesterol diet with amlodipine group (HE). 
The control group was fed with normal rabbit 
chow, whereas the high cholesterol diet groups 
were under a high cholesterol diet regime 
(2%). Cholesterol powder (Merck Company) 
was added to this normal food. NA and HE 
groups received amlodipine powder (Arya 
Company, Iran) 5 mg/kg/day. All the animals 
were housed in an environmentally controlled 
room. To eliminate
  the pharmacological 
effects, 24 hr before the performance of their 
experiments drugs were withdrawn in each 
group. All the experimental procedures 
including rabbit care and handling were 
performed in agreement with the guidelines 
provided by Experimental Animal Laboratory 
and approved by the Animal Care Committee 
of Tabriz University of Medical Sciences.  
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Serum lipid profile 
Serum lipid profile including total cholesterol 
and triglyceride were determined by enzymatic 
methods using automatic analyzer (Abbott, 
Alcyon 300, USA). 
 
The plasma ET-1 level 
Because of a local release of ET-1, blood 
samples gathered from the aortic
 root and the LV 
tissue were obtained for measuring
 of systemic 
and local ET-1 levels at the end of the study. At
 
the completion of experiment, animals 
anaesthetized with thiopenton (50 mg/kg/ip). 
Then left ventricles rapidly isolated after 
removal of the hearts. Blood was also stored in 
tubes containing EDTA (10 mmol/1 final 
concentration) treated on ice for determination of 
the plasma endothelin. After centrifugation (15 
min, 4 °C), the plasma (1ml) was  stored  at          
-80 °C until analysis. The level of the plasma 
ET-1 was measured by special kit of ET-1 (Titer 
Zyme® EIA kit, No: 030806265).  
 
Cardiac ET-1 level                               
For the measurement of cardiac ET-1 levels, 
each left ventricular tissue was weighed 
individually. The tissues were immediately 
homogenized with a homogenizer in a buffer 
containing HCl-20 mmol/l, Acetic acid-
1mmol/l which followed by centrifugation of
 
the homogenized preparation (3000 g for 10 
min at 4 °C). The light supernatant obtained 
from homogenization was stored at -80 °C 
until needed. Following the endothelin 
measurement time, the supernatant was 
lyophilized by lyophilizer (Christ Alphal-4) 
and the level of heart tissue ET-1 was 
measured
 by special kit of ET-1. 
 
RNA extraction and RT-PCR analysis  
Total RNA from left ventricular cells was 
extracted using TRIZOl
 reagent (In vitro gen) 
according to the manufacturer's instructions. 
Total RNA (5 µg) was treated with 1 µg oligo 
(dT) and AMV reverse transcriptase using 
first-strand cDNA synthesis kit (Fermentas). 
The reaction was performed at 42 °C for 
60 min. One µl of cDNA was used to perform 
PCR. The primer sets were as follows: Rab-
ET1-F, GCTCCTGCTCCTCGCTGAT and 
Rab-ET1-R, AGAGCGAGTGAGAGAGTGA, 
βactin primer-F: 5΄- CCC TAA GGC CAA 
CCG TGA AAA GAT G -3΄and  β actin 
primer-R: 5΄- GAA CCG CTC ATT GCC 
GAT AGT GAT G-3΄. The cycle profile 
included denaturation for 60 sec at 94 °C,
 
annealing for 45 sec at 57 °C, and extension
 
for 1 min at 72 °C. The amplified PCR 
products were electrophoresed on 1% agarose 
gels, stained with ethidium bromide and 
visualized by ultraviolet transilluminator. The 
relative intensities of signals
  were quantified 
using scion image software (Scion Corporation 
USA).  
 
Statistical analysis                 
Results were presented as means±SD. Data 
were analyzed
 with SPSS. Two-way ANOVA 
was used to search for
 possible effects of ET-1 
levels, cholesterol levels, and if an F-value 
was found to be significant, a two-tailed
 
Student's t-test was used to test differences. 
Correlation
 between the ratio of LV mass/body 
weight and ET-1 levels were assessed by 
Pearson's correlation coefficient. The 
significant level was assumed at value of              
P< 0.05.
  
 
Results         
The assessment of high cholesterol diets 
Our results clearly demonstrated that 8 weeks 
of high cholesterol diets (2%) significantly 
increased the level of total serum cholesterol 
and  triglyceride.  These  observations          
indicate that atherogenic diet induced 
hypercholesterolemia in our experimental New 
Zealand rabbit model (Table 1). After 8 weeks 
of high cholesterol diet, the hyperlipidemic 
rabbits
 had a significantly higher ratio of LV 
weight to body weight
 than that of the control 
group (2.08±0.09 vs. 1.66±0.07 g/kg in 
controls, P< 0.001). A significant
 reduction in 
LV mass occurred after amlodipine treatment 
by
  12% (P< 0.01). There was a significant 
residual LV hypertrophy
  after amlodipine 
treatment, being 4% above that in control
        
(P< 0.05).  
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Table 1. Comparison of the body weight, LV weight/body weight (g/kg) and serum lipid profile changes (mg/dl) among 
four groups of New Zealand rabbits.  
Parameters NC  NA  HC  HA 
N 8  8  8  8 
Body weight, kg  2.4±0.1  2.4±0.1  2.3±0.1  2.3±0.1 
LV weight/body weight, g/kg  1.66±0.07  1.65±0.07  2.08±0.09
*  1.73±0.07
** 
Plasma cholesterol, mg/dl  49.1 ± 0.6  40.3±0.8  860.3±0.6
*  524.5±5.8
** 
Plasma triglyceride, mg/dl  95.5±1.7  81.0±0.5  466.6±2.5
*  138.6±1.8
** 
Abbreviations: NC= normal diet control; NA= normal diet with amlodipine; HC= high cholesterol diet control;           
HA= high cholesterol diet with amlodipine; N= the number of rabbits in each group. 
; LV= left venticular 
* Significant difference with NC group (P=0.001); ** Significant difference with HC group (P=0.001) 
  
Circulating, myocardial ET-1 Levels and 
prepro-ET-1 mRNA in myocardial tissue 
The plasma level of ET-1 in atherosclerotic 
model group was significantly increased as 
compared with the control group (P< 0.01). 
After treatment with amlodipine for 8 weeks   
ET-1 level was reduced significantly in the 
control (P= 0.01) and high-cholesterol diet 
rabbits P= 0.01) (Table 2).
 
To  investigate  the  possible  role  of  cardiac        
ET-1 synthesis
 in the reduction of the plasma 
ET-1 levels, we determined the ventricular
 ET-1 
levels. Amlodipine consumption caused 
significant reduction (P= 0.01) in the level of 
endothelin-1 in heart tissue of high-cholesterol 
diet group but didn't have any significant affect 
on the reduction of heart tissue endothelin-1 in 
amlodipine  group  compared  with  control        
(Table 2). The mRNA
  levels of prepro-ET-1 
showed a 1.8±0.2-fold enhancement in the 
hyperlipidemic rabbits (P= 0.0001;
  Figure 2). 
Thus  the  mRNA  levels  of  prepro-ET-1               
were changed in parallel
  to  the  tissue  peptide          
levels, indicating that the production of
 prepro-
ET-1  is  a  critical  regulation  step  for                   
its local activation.
  Amlodipine administration 
significantly decreased both prepro-ET-1
 mRNA 
and ET-1 peptides compared with rabbits 
untreated with amlodipine, implicating that 
amlodipine has inhibitory
 effect on ET-1 levels. 
 
Correlation 
The linear regression models showed a 
significant correlation
 between tissue ET-1 levels 
and the ratio of LV mass to body
  weight              
(LV mass-to-body weight ratio= 0.004 x tissue 
ET-1 levels
 (in pg/mg protein)+1.502, P= 0.000) 
(Figure  3). 
 
Table 2. Comparison of plasma and tissue endothelin 
changes among four groups of New Zealand rabbits.  
Group 
Plasma 
Endothelin 
(pg/ml) 
Heart Tissue Endothelin 
(pg/100mgTissue) 
NC  0.56± 0.01  0.31 ± 0.02 
NA  0.39 ± 0.01
* 0.27  ±  0.01 
HC 0.8  ±  0.04
*  0. 47 ± 0.02 
 * 
HA  0.6 ± 0.01
 # 0.37  ±  0.02 
# 
Data are expressed as Mean±SEM (n= 8) for each 
group. 
Differences of P< 0.05 were considered significant.  
* NA and HC vs. NC
  # HA vs. HC  (Plasma Endothelin) 
* NA and HC vs. NC
 # HA vs. HC (Heart Tissue 
Endothelin) 
Abbreviations: NC= normal diet control; NA=normal 
diet with amlodipine; HC= high cholesterol diet control; 
HA=high cholesterol diet with amlodipine. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Comparison of left ventricular mass indexed 
by body weight (BW) among four groups of New 
Zealand rabbits. 
* NA and HC vs. NC
 # HA  vs.  HC         
(P< 0.05)                                         
NC= normal diet control; NA=normal diet with 
amlodipine; HC= high cholesterol diet control; HA= 
high cholesterol diet with amlodipine.  
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Figure 2. Comparison of LV prepro-endothelin-1 mRNA 
levels in among four groups of New Zealand rabbits.  
* NA 
and HC vs. NC
 # HA vs. HC (P< 0.05) 
Data are expressed as Mean±SEM (n= 10) for each group. 
  Abbreviations: NC=normal diet control; NA=normal 
diet with amlodipine; HC= high cholesterol diet control; 
HA=high cholesterol diet with amlodipine. Each mRNA 
was corrected for an mRNA level of β- actin. (LV mass-
to-body weight ratio= 0.004 x tissue ET-1 levels
               
(in pg/mg protein) + 1.502, P= 0.000). 
 
 
Figure 3. ET-1 concentration of the LV in relation to 
LV mass/BW.  
ETBG: Endotheline gene expression.  
LW.BW: Ratio of left ventricular weight to body weight 
 
Discussion 
The results obtained in this research clearly 
showed that 8 weeks consumption of high 
cholesterol diets (2%) significantly increased 
serum total cholesterol and triglyceride. Our 
observations indicated that atherogenic diet 
induced hypercholesterolemia in our 
experimental New Zealand rabbit model 
(Table 1). The concentration of plasma 
cholesterol in hyperlipidemic rabbits showed 
higher effects significantly. Treatment with 
amlodipine decreased the concentration of 
plasma cholesterol considerably in comparison 
with hyperlipidemic rabbits. Amlodepine 
effect on decreased endotheline gene 
expression and tissue concentration seems to 
be related to its effect on the plasma 
cholesterol concentration. Moreover, GA 
modifies cholesterol metabolism and regulates 
the deposition of cholesterol in arterial wall 
(16). The results of this study show that 
hyperlipidemic rabbits
 had significantly higher 
ratio of LV weight to body weight
 than that of 
the control group. A significant
  reduction in 
LV mass occurred after amlodipine treatment. 
There was a considerable residual LV 
hypertrophy
  after amlodipine treatment.
  
Figure 1 shows the comparison of left 
ventricular mass indexed by body weight 
(BW) among four groups of New Zealand 
rabbits. The linear regression models 
demonstrated an important correlation
 between 
tissue ET-1 levels and the ratio of LV mass to 
body
 weight. Regarding to ET-1 concentration 
of the LV in relation to LV mass/BW, a 
remarkable correlation was found between the 
2 variables (Figure 3). The present study 
showed two novel findings utilizing
  the
 
combined use of molecular and biochemical 
methods, fascinating new insight into the 
nature of amlodipine and endothelin. First, 
hyperlipidemia acting through
  the increasing 
levels of ventricular prepro-ET-1 mRNA and
 
tissue ET-1 which results in the progress of 
ventricular
  hypertrophy. It in turns may be 
inhibited by using CBBs. Second, we found 
that amlodipine administration had the positive
 
effects on the attenuated ventricular 
hypertrophy at the development stage of LV 
hypertrophy
  via attenuation of tissue ET-1 
levels. Regarding to hyperlipidemia and LV 
mass, our results showed that 
hypercholesterolemia was correlated with
 
increased LV mass. However, attention should 
be drawn to other potential mechanisms such 
as local activation of ET-1 which might be 
associated
  with the ventricular hypertrophy 
progression but it depends on the levels of   
ET-1 in the plasma. As far as we are aware, 
several studies in hyperlipidemic
 rabbits, have 
reported the significant
  increased levels of   
ET-1 by vascular endothelium cells (17) but 
the release
 of
 local ET-1 by myocardium has 
ETBG
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not been previously addressed. We showed 
that the enhanced levels of ET-1 in tissues 
were effective in the progression of ventricular
 
hypertrophy induced in hypercholesterolemia. 
Our results are in agreement with the previous 
studies which showed the raised level of ET-1 
secreted from
  coronary vascular cell wall to 
myocardium.
  At least 3 classes of signaling
 
pathways in the cardiomyocytes, including 
mitogen-activated
  protein kinase, protein 
kinase C, and the phosphatidylinositol 3-
kinase/Akt are activated by ET-1. ET receptor 
blockers suppress the increased synthesis of 
protein
  and the activation of these signaling 
pathways  in
  vitro and in vivo studies. This 
observation raises the possibility that the
 ETA 
receptor has been attributed at least in part in 
ET-1-induced
  hypertrophic growth (18). Our 
findings are also in agreement with 
cardioprotection of amlodipine which is 
exerted
 by chronic inhibition of ET-1 levels. 
However, angiotensin II and free radicals are 
the other possible
  mechanisms which are 
considered to modulate the antihypertrophic 
effects of
 amlodipine. Angiotensin
 II and ET-1, 
as a complex compose, show positive circuit 
acting on
 cardiomyocytes. Studies
 have shown 
a correlation between the angiotensin system
 
and ET-1 in vitro so that the angiotensin II 
may induce
 ET-1 synthesis in cardiomyocytes 
(19). Ishiye et al have reported the inhibition 
of enhancement in ventricular
 ET-1 content by 
specific blockade of angiotensin
  type                     
1 receptors (20). Amlodipine has been 
reported which may inhibit the
  activity of 
angiotensin II (21), so it is considered as a 
factor for the down regulation
  effect on the 
expression of ET-1 protein. Moreover, 
blockade of
 free radicals delays the progress of 
cardiac hypertrophy (22). Previously it has 
been shown that cardiac protection of Ca-
blockers may be correlated with the decrease 
of myocardial oxidative stress (23). Increased 
production of free radicals
  activates the 
mitogen-activated
  protein kinases which 
results in induction of cardiac hypertrophy 
(24). Thus, it seems that amlodipine may have 
a role to attenuate cardiac
  hypertrophy by 
reducing the production of free radicals. 
Although previous studies in humans have 
shown the association of the hyperlipidemia
 
with increased LV mass (25), in this model 
hypercholesterolemia rabbits developed
 
ventricular hypertrophy.
 However, this makes 
it difficult to make a firm conclusion about the 
direct effects of hyperlipidemia on the cardiac
 
hypertrophy, because there are several factors 
which are involved in interpreting
 of LV mass 
in clinical settings. In the present research to 
investigate the
 direct effect of hyperlipidemia 
on myocyte hypertrophy, we utilized the 
hyperlipidemic model. We confirmed that 
amlodipine administration
 has an effect on the 
hypertrophic signaling in hyperlipidemia 
rabbits,
 via interfering on the activities of ET-1 
pathways.
  The  dose  of  amlodipine                  
(1.2 mg/kg/day) used
  in this study was 
considered safe and was similar to the 
conventional
  dose of amlodipine utilized in 
humans (up to 80 mg/kg/day). Therefore, this 
beneficial effect of amlodipine therapy may 
have
 significant application in clinic.
  
 
Conclusion 
The present research showed that the level of 
ventricular
  prepro-ET-1 mRNA was 
quantitatively increased by the high-
cholesterol
 diet resulted in increasing of tissue 
ET-1
 levels. This in turn caused in the progress 
of ventricular hypertrophy. Treatment with 
amlodipine influences on
 the development of 
LV hypertrophy possibly through reduction
 of 
ET-1 levels independent of lipid changes. 
These findings
 may be considered significant 
in LV mass-related risk factors of 
hyperlipidemic
  patients. Most selected 
treatments of hyperlipidemia should not only
 
focus on adequate reduction of cholesterol but 
might also consider concomitant
 reduction of 
LV mass, which may help the scientists to fill 
in the considerable gaps which remains to be 
clarified in the complex
  puzzle of the drug 
interactions with the heart. 
 
 
Acknowledgment                
This work was supported in part by a grant 
from Drug Applied Research Center of Tabriz 
University of Medical Sciences, Tabriz, Iran. 
We wish to thank Professor Hossein Babaei, 
for his support and advices.   
Iraj Salehi et al 
   Iran J Basic Med Sci, Vol. 13, No. 4, Autumn 2010    238 
References 
1. James PT, Rigby N, Leach R. International obesity task Force. The obesity epidemic, metabolic syndrome and 
future prevention strategies. Eur J Cardiovasc Prev Rehabil 2004; 11:3–8. 
2. Alpert MA. Obesity cardiomyopathy: pathophysiology and evolution of the clinical syndrome. Am J Med Sci 
2001; 321:225–236. 
3. Hubert HB, Feinleib M, McNamara PM, Casteelii WP. Obesity as an independent risk factor for cardiovascular 
disease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation 1983; 67:9 68–77. 
4. Kenchaiah S, Evans JC, Levy D, Wilson PW, Benjamin EJ, Larson MG, et al. Obesity and the risk of heart 
failure. N Engl J Med 2002; 347:305–313. 
5. Sadoshima J, Izumo S. The cellular andmolecular response of cardiac myocytes to mechanical stress. Annu Rev 
Physiol 1997; 59:551–571. 
6. Castelli WP, Anderson K. A population at risk: prevalence of high cholesterol levels in hypertensive patients of 
the Framingham Study. Am J Med 1986; 23–32.  
7. Bohn F, Johansson B, Hedin U, Alving K, Pernow J. Enhanced vasoconstrictor effect of big endothelin–1 
patients with athrosclerosis : relation to conversion to endothelin – 1 .Atherosclerosis 2002; 160:215–222. 
8. Lerman A, Webster MW, Chesebro JH, Edwards WD, Wei CM, Fuster V, et al. Circulating and tissue 
endothelin immnoreactivity in hypercholesterolemic pigs. Circulation  1993; 88:2923–2928.  
9. Haak T, Marz W, Jungmann E, Hausser S, Siekmeier R, Gross W, et al. Elevated endothelin levels in patients 
with hyperlipidemia. Clin Investig 1994; 72:580–584. 
10. Yue TL, Gu JL, Wang C, Reith AD, Lee JC, Mirabile RC, et al. Extracellular signal-regulated kinase plays an 
essential role in hypertrophic agonists, endothelin-1 and phenylephrine-induced cardiomyocyte hypertrophy. J 
Biol Chem  2000; 275:37895-378901. 
11. Davenport AP,Maguire JJ. Of mice and men: advances in endothelin research and first antagonist gains FDA 
approval. Trends Pharmacol Sci 2002; 23:155–157.  
12. Waters D, Lesperance J, Francetich M, Causey D, Theroux P, Chiang YK, et al. A controlled clinical trial to 
assess the effect of a calcium channel blocker on the progression of coronary atherosclerosis. Circulation 1990; 
82:1940-1953. 
13. Pitt B, Byington RP, Furberg CD, Hunninghake DB, Mancini GB, Miller ME, et al. Effect of amlodipine on the 
progression of atherosclerosis and the occurrence of clinical events. PREVENT Investigators. Circulation  2000; 
102:1503-1510. 
14. Jukema JW, Zwinderman AH, van Boven AJ, Reiber JH, Van der Laarse A, Lie KI, et al. Evidence for a 
synergistic effect of calcium channel blockers with lipid-lowering therapy in retarding progression of coronary 
atherosclerosis in symptomatic patients with normal to moderately raised cholesterol levels. The REGRESS 
Study Group. Arterioscler Thromb Vasc Biol 1996; 16:425-430. 
15. Catapano AL. Calcium antagonists and atherosclerosis. Experimental evidence. Eur Heart J 1997; 18:A80-86. 
16. Bellosta S, Bernini F. Lipophilic Calcium Antagonists in Antiatherosclerotic Therapy. Current Atherosclerosis 
Reports 2000; 2:76–81. 
17. Mitani H, Takimoto M, Bandoh T, Kimura M. Increases of vascular endothelin-converting enzyme activity and 
endothelin-1 level on atherosclerotic lesions in hyperlipidemic rabbits. Eur J Pharmacol  2000; 387:313-319. 
18. Sugden PH. Signaling pathways activated by vasoactive peptides in the cardiac myocyte and their role in 
myocardial pathologies. J Card Fail 2002; S359-369. 
19. Ito H, Hirata Y, Adachi S, Tanaka M, Tsujino M, Koike A, et al.Endothelin-1 is an autocrine/paracrine factor in the 
mechanism of angiotensin II-induced hypertrophy in cultured rat cardiomyocytes. J Clin Invest 1993; 92:398-403. 
20. Ishiye M, Umemura K, Uematsu T, Nakashima M. Angiotensin AT1 receptor-mediated attenuation of cardiac 
hypertrophy due to volume overload: involvement of endothelin. Eur J Pharmacol  1995; 280:11-7. 
21. Warnholtz A, Nickenig G, Schulz E, Macharzina R, Brasen JH, Skatchkov M, et al. Increased NADH-oxidase-
mediated superoxide production in the early stages of atherosclerosis: evidence for involvement of the renin-
angiotensin system. Circulation 1999; 99:2027-2033. 
22. Hu CT, Chang HR, Hsu YH, Liu CJ, Chen HI. Ventricular hypertrophy and arterial hemodynamics following 
deprivation of nitric oxide in rats. Life Sci  2005; 78:164-173. 
23. Castro GJ, Bhatnagar A. Effect of extracellular ions and modulators of calcium transport on survival of tert-
butyl hydroperoxide exposed cardiac myocytes. Cardiovasc Res 1993; 27:1873-1881. 
24. Takemoto M, Node K, Nakagami H, Liao Y, Grimm M, Takemoto Y, et al. Statins as antioxidant therapy for 
preventing cardiac myocyte hypertrophy. J Clin Invest 2001; 108:1429-1437. 
25. Lee TM, Chou TF, Tsai CH. Association of pravastatin and left ventricular mass in hypercholesterolemic 
patients: role of 8-iso-prostaglandin f2alpha formation. J Cardiovasc Pharmacol 2002; 40:868-874. 
 
  